Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.29 | 0.24 | 0.33 | 0.31 | 0.30 | 0.59 | 0.33 | 0.36 | 0.43 | 0.38 | 0.22 | 0.05 |
| Operating Profit | -0.29 | -0.24 | -0.33 | -0.31 | -0.30 | -0.59 | -0.33 | -0.36 | -0.43 | -0.38 | -0.22 | -0.05 |
| OPM % | ||||||||||||
| Other Income | -1.11 | 0.04 | 0.80 | 0.23 | 0.27 | 0.46 | 0.32 | 0.22 | 0.30 | 0.22 | 11.29 | 0.17 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -1.42 | -0.22 | 0.45 | -0.10 | -0.05 | -0.17 | -0.03 | -0.16 | -0.15 | -0.17 | 10.99 | 0.12 |
| Tax % | -27.46% | -4.55% | 28.89% | -20.00% | -20.00% | -147.06% | 1,400.00% | -75.00% | 33.33% | -23.53% | 24.20% | 25.00% |
| Net Profit | -1.03 | -0.20 | 0.32 | -0.08 | -0.04 | 0.09 | -0.45 | -0.03 | -0.19 | -0.13 | 8.33 | 0.09 |
| EPS in Rs | -42.04 | -8.16 | 13.06 | -3.27 | -1.63 | 3.67 | -18.37 | -1.22 | -7.76 | -5.31 | 340.00 | 3.67 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23.11 | 18.06 | 34.99 | 12.35 | 20.03 | 13.94 | 8.82 | 0.00 | 0.00 | -0.01 | -0.03 | 0.00 |
| Expenses | 22.11 | 17.07 | 31.18 | 10.71 | 15.48 | 14.30 | 7.47 | 1.33 | 1.05 | 1.21 | 1.34 | 1.08 |
| Operating Profit | 1.00 | 0.99 | 3.81 | 1.64 | 4.55 | -0.36 | 1.35 | -1.33 | -1.05 | -1.22 | -1.37 | -1.08 |
| OPM % | 4.33% | 5.48% | 10.89% | 13.28% | 22.72% | -2.58% | 15.31% | |||||
| Other Income | -0.01 | 0.16 | 0.41 | 0.06 | 0.47 | 0.13 | 0.55 | 0.27 | -0.19 | 1.05 | 12.03 | 11.98 |
| Interest | 0.20 | 0.07 | 0.40 | 0.46 | 0.30 | 0.21 | 0.02 | 0.00 | 0.00 | 0.00 | 0.10 | 0.08 |
| Depreciation | 0.27 | 0.28 | 0.25 | 0.21 | 0.17 | 0.14 | 0.12 | 0.11 | 0.09 | 0.08 | 0.05 | 0.03 |
| Profit before tax | 0.52 | 0.80 | 3.57 | 1.03 | 4.55 | -0.58 | 1.76 | -1.17 | -1.33 | -0.25 | 10.51 | 10.79 |
| Tax % | 32.69% | 28.75% | 28.57% | 29.13% | 25.27% | -24.14% | 25.00% | -24.79% | -24.06% | 60.00% | 24.17% | |
| Net Profit | 0.34 | 0.58 | 2.56 | 0.74 | 3.40 | -0.45 | 1.32 | -0.89 | -1.01 | -0.40 | 7.97 | 8.10 |
| EPS in Rs | 13.88 | 23.67 | 104.49 | 30.20 | 138.78 | -18.37 | 53.88 | -36.33 | -41.22 | -16.33 | 325.31 | 330.60 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | 200% | ||
| Compounded Profit Growth | % | % | % | 7% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | 0% | -10% | -16% | -35% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Reserves | 4.31 | 4.65 | 5.24 | 7.79 | 8.53 | 11.93 | 11.47 | 12.80 | 11.35 | 14.38 | 13.42 | 20.40 |
| Borrowings | 3.50 | 0.00 | 2.86 | 2.28 | 5.79 | 2.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.42 | 2.12 | 1.93 | 1.47 | 0.58 | 1.94 | 0.38 | 0.28 | 0.24 | 0.25 | 0.23 | 0.23 |
| Total Liabilities | 8.48 | 7.02 | 10.28 | 11.79 | 15.15 | 16.62 | 12.10 | 13.33 | 11.84 | 14.88 | 13.90 | 20.88 |
| Fixed Assets | 1.72 | 1.85 | 1.64 | 1.42 | 1.22 | 1.06 | 0.94 | 0.87 | 0.77 | 0.68 | 0.60 | 0.00 |
| CWIP | 0.37 | 0.04 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.12 | 3.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.42 | 11.07 | 10.63 | 7.89 |
| Other Assets | 6.27 | 1.45 | 8.64 | 10.37 | 13.93 | 15.53 | 11.13 | 12.46 | 1.65 | 3.13 | 2.67 | 12.99 |
| Total Assets | 8.48 | 7.02 | 10.28 | 11.79 | 15.15 | 16.62 | 12.10 | 13.33 | 11.84 | 14.88 | 13.90 | 20.88 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 2.34 | 6.79 | -6.48 | 1.45 | -3.75 | 3.82 | 10.25 | 3.47 | -1.03 | -3.76 | 0.20 | -2.87 |
| Cash from Investing Activity | -0.10 | -3.70 | 3.71 | -0.01 | 0.02 | -0.03 | 0.00 | 0.16 | -9.82 | 3.34 | 0.17 | 13.70 |
| Cash from Financing Activity | -1.69 | -3.68 | 2.80 | -0.92 | 3.06 | -3.49 | -2.61 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash Flow | 0.56 | -0.59 | 0.03 | 0.52 | -0.67 | 0.30 | 7.64 | 3.61 | -10.85 | -0.42 | 0.37 | 10.82 |
| Free Cash Flow | 2.24 | 6.68 | -6.51 | 1.42 | -3.76 | 3.79 | 10.23 | 3.44 | -1.03 | -3.76 | 0.20 | 8.85 |
| CFO/OP | 241% | 682% | -635% | 56% | -176% | 106% | -2,939% | 287% | 105% | 351% | -17% | 64% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 2.02 | 0.00 | 49.52 | 0.00 | 98.42 | 225.96 | 36.40 | 0.00 | 0.00 | 0.00 | ||
| Inventory Days | 55.65 | 5.85 | 52.93 | 104.38 | 414.36 | 41.57 | 24.60 | 2.90 | 0.00 | 0.00 | ||
| Days Payable | 1.45 | 31.02 | 36.57 | 9.13 | 14.72 | 19.85 | 9.26 | 9.85 | ||||
| Cash Conversion Cycle | 56.22 | -25.17 | 65.88 | 95.24 | 498.06 | 247.68 | 51.74 | -6.95 | 0.00 | 0.00 | ||
| Working Capital Days | 16.06 | -19.43 | 63.06 | 56.23 | 216.64 | 190.79 | 63.10 | 0.83 | 50,735.00 | 14,965.00 | ||
| ROCE % | 11.78% | 11.57% | 12.83% | 42.53% | 11.97% | 33.16% | -2.80% | 14.45% | -10.14% | -2.67% | -3.32% | -4.37% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% | 68.65% |
| Public | 31.36% | 31.36% | 31.36% | 31.36% | 31.36% | 31.36% | 31.35% | 31.35% | 31.35% | 31.35% | 31.35% | 31.35% |
| No. of Shareholders | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 54 | 54 | 55 |
Fundamentals
Market Cap₹ Cr.
Current Price₹ 17.4
Book Value₹ 843
ROCE-4.37 %
ROE-34.6 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)200%
Compounded Profit Growth (TTM)7%
Standalone figures.
Valuation
P/E, 3-year average0.05x
P/B, 3-year average0.03x
P/E, 5-year average0.19x
P/B, 5-year average0.03x
Profitability
Operating margin (excl. other income)4566.67%
Operating margin (incl. other income)-35533.33%
EBITDA margin-36466.67%
Pre-tax margin-35966.67%
Net profit margin-27000.00%
ROE46.45%
ROCE61.83%
ROA45.83%
ROE, 3-year average11.97%
ROCE, 3-year average16.64%
ROA, 3-year average11.83%
ROE, 5-year average7.87%
ROCE, 5-year average10.96%
ROA, 5-year average7.76%
ROIC (approx.)92.58%
Tax rate24.17%
Other income / net worth58.26%
Growth
Sales growth (latest year)200.00%
Profit growth QoQ-98.92%
Per share
EPS (TTM)Rs 330.61
EPS (latest year)Rs 325.31
EPS (latest quarter)Rs 3.67
EPS, 3-year averageRs 89.25
EPS, 5-year averageRs 57.06
Book value per shareRs 842.86
Sales per shareRs -1.22
Cash flow per shareRs -117.14
Free cash flow per shareRs 361.22
Efficiency
Asset turnover-0.00x
Creditor days10 days
Cash conversion cycle0 days
Working capital days14965 days
Leverage
Cash and bankRs 12 Cr
Net debtRs -12 Cr
Net debt / EBITDA-1.07x
Interest coverage108.90x
Owners' fund to total sources98.90%
Cash flow
Cash from Operating Activity (latest year)Rs -3 Cr
Cash from Investing Activity (latest year)Rs 14 Cr
Net Cash Flow (latest year)Rs 11 Cr
Free cash flow (latest year)Rs 9 Cr
Cash from ops / profit, 5 years-0.57x
Statement figures
Net sales (TTM)Rs -0 Cr
Net sales (latest year)Rs -0 Cr
Operating profit excl. other income (latest year)Rs -1 Cr
Operating profit (latest quarter)Rs -0 Cr
Other income (TTM)Rs 12 Cr
EBITDA (TTM)Rs 11 Cr
PBDT (TTM)Rs 11 Cr
Profit before tax (TTM)Rs 11 Cr
Tax (latest year)Rs 3 Cr
Net profit (TTM)Rs 8 Cr
Net profit (latest year)Rs 8 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 1 Cr
Total expenditure (latest year)Rs 1 Cr
Total income (latest year)Rs 12 Cr
Share capitalRs 0 Cr
ReservesRs 20 Cr
Shareholders' fundsRs 21 Cr
Total assetsRs 21 Cr
InvestmentsRs 8 Cr
Other liabilitiesRs 0 Cr
Shares outstanding (crore)0.02
Ownership
Promoter holding68.65% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 4 of 7| explain | Weak cash conversion Cash from operations was -98% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 52% of total assets in 2026 |
| look | Profit leans on other income Other income was 114% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹0 Cr.
Net profit ₹0 Cr +400.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Triochem Products Ltd?
Triochem Products Ltd (512101) has a market capitalisation of Rs Cr. at the close.
What were Triochem Products Ltd's latest quarterly results?
In the Jun 2026 quarter, Triochem Products Ltd sales was Rs 0 Cr and net profit was Rs 0 Cr.